Drug tested in LGMD2B/Miyoshi patients shows promise

Dr. Michael Sinnreich recently conducted a clinical study of a drug called bortezomib in individuals who have a particular type of mutation (called ‘missense mutations’) in the dysferlin gene. Read the full summary of the article here.